Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Reckova

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Development (Cambridge, England)|January 9, 2004
Hemodynamic-dependent patterning of endothelin converting enzyme 1 expression and differentiation of impulse-conducting Purkinje fibers in the embryonic heartChristopher E Hall, Romulo Hurtado, Kenneth W Hewett, et al.
Urologic Oncology|November 28, 2015
Phase II study of everolimus in refractory testicular germ cell tumorsMichal Mego, Daniela Svetlovska, Vera Miskovska, et al.
Complementary Therapies in Medicine|June 9, 2015
Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot studyMichal Mego, Jozef Chovanec, Iveta Vochyanova-Andrezalova, et al.
European Urology Open Science|November 5, 2021
Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II TrialMichal Mego, Katarina Rejlekova, Daniela Svetlovska, et al.
Frontiers in Oncology|August 6, 2024
The beneficial effect of probiotics in the prevention of irinotecan-induced diarrhea in colorectal cancer patients with colostomy: a pooled analysis of two probiotic trials (Probio-SK-003 and Probio-SK-005) led by Slovak Cooperative Oncology GroupMichal Mego, Barbora Kasperova, Jozef Chovanec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Development (Cambridge, England)|January 9, 2004
Hemodynamic-dependent patterning of endothelin converting enzyme 1 expression and differentiation of impulse-conducting Purkinje fibers in the embryonic heartChristopher E Hall, Romulo Hurtado, Kenneth W Hewett, et al.
Urologic Oncology|November 28, 2015
Phase II study of everolimus in refractory testicular germ cell tumorsMichal Mego, Daniela Svetlovska, Vera Miskovska, et al.
Complementary Therapies in Medicine|June 9, 2015
Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot studyMichal Mego, Jozef Chovanec, Iveta Vochyanova-Andrezalova, et al.
European Urology Open Science|November 5, 2021
Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II TrialMichal Mego, Katarina Rejlekova, Daniela Svetlovska, et al.
Frontiers in Oncology|August 6, 2024
The beneficial effect of probiotics in the prevention of irinotecan-induced diarrhea in colorectal cancer patients with colostomy: a pooled analysis of two probiotic trials (Probio-SK-003 and Probio-SK-005) led by Slovak Cooperative Oncology GroupMichal Mego, Barbora Kasperova, Jozef Chovanec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
Pageof 2